The recorded searches did not identify a clinical trial administering retatrutide with MOTS-c. Individual-drug or endogenous-biomarker findings cannot establish the combination’s benefit, interaction profile or product quality [12].
Untested as a pair, and neither drug is approved
FDA's position on retatrutide is direct: it "cannot be used in compounding under federal law," it is not part of any approved drug, and it has not been found safe and effective for any condition [1]. It isn't on FDA's list of new drugs approved in 2026 [2].
MOTS-c is in a similar spot. It has no monograph, isn't part of an approved drug and isn't on the list pharmacies may compound from [3]. Its legal status is covered in whether you can buy MOTS-c legally.
The recorded searches identified no combination trial
The recorded combination registry query returned no study, and the indexed literature query returned three reviews rather than an administered-combination trial [12]. NCT07505745 tests MOTS-c against placebo without retatrutide and has no results [11].
An indirect biomarker study illustrates the distinction. A 2025 study measured the body's own MOTS-c in 163 people with type 2 diabetes taking an older GLP-1 drug, liraglutide, or other diabetes medicines [4]. Nobody in it received MOTS-c, and retatrutide wasn't involved.
Retatrutide: strong trial results, but still investigational
Retatrutide acts on three hormone receptors at once (GIP, GLP-1 and glucagon), and its trial results are large. In the phase 3 TRIUMPH-1 trial of 2,339 adults with obesity and no diabetes, mean weight fell 25.0% at 80 weeks on the highest dose, against 3.9% on placebo [5]. Eli Lilly, the sponsor, funded the trial.
Further phase 3 trials found weight loss in people with type 2 diabetes and lower A1C in early type 2 diabetes [6] [7]. The most common side effects were digestive. In the phase 2 trial, heart rate rose with dose, peaked at 24 weeks and then declined [8].
Those numbers belong to the sponsor's drug, made to trial standards and given under a protocol with medical follow-up. They say nothing about what is in a vial sold online as "reta," or how it behaves.
MOTS-c: preclinical findings and a trial without results
The FDA briefing reports no human treatment/exposure data identified within its assessment [3]. The current trial protocol nevertheless exists and has no posted results. The fat-loss review and timing review explain the difference.
| Retatrutide | MOTS-c | |
|---|---|---|
| FDA status | Investigational, not approved | Not approved |
| Can pharmacies compound it? | No (FDA) | No (FDA) |
| Human trials | Phase 3 completed (TRIUMPH-1, TRIUMPH-2, TRANSCEND-T2D-1) | Reviewed native-MOTS-c protocol recruiting, with no posted results |
| Best-known effect | Up to 25.0% mean weight loss at 80 weeks (sponsor's drug) | Less weight gain in mice |
| Known human side effects | Digestive effects, heart-rate rise (trials) | Unknown |
| Tested together | No | No |
Sources: FDA GLP-1 concerns page, FDA MOTS-c briefing (July 2026), NEJM and Lancet trial reports.
Two unstudied products add unknowns, not answers
Both compounds are pitched for metabolism. Retatrutide lowered A1C in its trials [7]. MOTS-c was studied for insulin sensitivity in mice [9]. That overlap is the reason the pair is marketed together, and it is also the reason caution makes sense: no one has measured how the two interact in a person.
An interaction study is the kind of work a drug sponsor does before approval. Neither product has reached that point together, so the honest answer about combined effects, good or bad, is that they're unknown.
What's actually in a "research" vial is uncertain
FDA warns that GLP-1-type drugs sold illegally online may be counterfeit, may hold the wrong or harmful ingredients, or may contain too much, too little or none of the active drug [1]. FDA has warned companies selling retatrutide and similar drugs "falsely labeled" for research, noting the products were sold to consumers with dosing instructions.
The reviewed FDA assessment identifies important characterization gaps; FDA's reviewers called it poorly characterized [3]. A vial sold as a combination stacks two of these uncertainties in one product. The safety questions for MOTS-c alone are in is MOTS-c safe.
Athletes face a separate problem with MOTS-c
WADA's 2026 Prohibited List names MOTS-c under S4.4.1, metabolic modulators, which are banned in and out of competition [10]. Anti-doping labs already have a validated blood test for it. How that test works, and what is known about how long MOTS-c lasts in the body, is in how long MOTS-c stays in your system.
Better questions to bring to a prescriber
- Which FDA-approved weight-management drugs fit my health history?
- Am I eligible for any registered trial, including trials of drugs not yet approved?
- Which labs should be checked before and during treatment? (That's your prescriber's call.)
- If a provider offers a peptide "stack," which pharmacy makes it, and under which FDA route?
The last question is one every provider check on this site asks, because a named pharmacy alone does not establish assignment, quality or authorization.